U.S. Markets open in 7 hrs 6 mins

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
5.10+0.07 (+1.39%)
At close: 4:00PM EDT
People also watch
NVAXHEBVICLARRYAGEN
  • KTOV = Mcap $16 Mil /Cash $17 Mil /Low float O/S 10 M / NDA submission for Big Drug this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension
    https://baystreet.ca/articles/research_reports/lifesci/Kitov062717.pdf

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

    “KIT-302 has the potential to address the multi-billion dollar market for the treatment of osteoarthritis pain and hypertension with one drug that reduces patients’ risk of suffering a heart attack or stroke, while also reducing cost for payers. There is currently no single medication on the market that treats both osteoarthritis pain and hypertension and thus, KIT-302 will be the only NSAID indicated both to treat pain and to reduce the risk of heart attack, stroke and death.”

    Pain medications for osteoarthritis account for billions of dollars in annual sales globally. Most pain medications for osteoarthritis, including celecoxib which had global sales of $2.7 billion in 2014, are non-steroidal anti-inflammatory drugs (NSAIDs) which have the side effect of elevating blood pressure, and increasing the risk of heart attacks, strokes and death. Of the 27 million Americans who live with osteoarthritis, 13.5 million also suffer from hypertension, which also increases the risk of heart attack, stroke, and death.

  • DO I HAVE THIS BCRX PICTURE CORRECT.....MEANING ,
    There was a secondary offering middle march for $8.50... & now we are at $5.41 ??? Did the bankers do their home work to protect there clients ??? I do not think they did... Well BCRX must now be a DEAL or A Bad Deal...... It will be important to see which FUNDS increased or decreased there position..... Being that R A Cap & Brothers are in , this must be a Deal...at todays price... Any thoughts on this ???
  • I can not find the recent Secondary Offering Share price.... What was the share price of the last offering,,, THX
  • [!] Just updated to now display all available spreads - Option traders pay a visit to CreditSpreads.io, absolutely free live table of statistically gainful option credit spreads for the next month, sometimes including spreads for BCRX! High probability option credit spreads offer you an effective way to invest with defined risk and the max profit gained up front. CreditSpreads.io lazer-targets solely the credit spreads which fulfill its strict requirements for probability and profit, and ensures continued profitability by warning you of any upcoming situations which could affect the trade. http://www.creditspreads.io

    CreditSpreads.io
    Sustainable, high probability, defined risk stock option trading opportunities.
    www.creditspreads.io
  • [!] Just upgraded to now display all available spread combinations - Option spread traders check out CreditSpreads.io, cost free live feed of mathematically gainful option credit spreads for the following month, sometimes including spreads for BCRX! High probability option credit spreads provide you with a solution to trade with determined risk and the max profit gained up front. CreditSpreads.io lazer-targets solely the credit spreads which satisfy its rigid standards for risk and profit, and ensures continued profitability by warning you of any future situations which may affect the trade. http://creditspreads.io

    CreditSpreads.io
    Sustainable, high probability, defined risk stock option trading opportunities.
    creditspreads.io
  • Monster Microcaps Alert to BCRX shareholders. Clean Energy Technologies Moving broke out 4 weeks ago and is beginning to move again - CETY - price today $.02. Price target $.20 by year end. Clean Energy Technologies. CETY recently announced expansion with their Europe Sales and Service Center for Europe new sales and to serve 65 existing customers with CETY’s General Electric clean energy Heat Recovery Systems and just announced they have already sold the first of SEVERAL HUNDRED units to come over next 24 months.

    Each CETY Heat Recovery System sells for $300,000 and market demand is several BILLION DOLLARS.

    CETY purchased Heat Recovery Systems Division from General Electric and products are now very attractive to huge unmet markets and can achieve over $250 million in sales within the next 2 years. Demand for conversion of wasted heat to electrical energy in big applications is VERY LARGE AND UNMET.

    https://finance.yahoo.com/news/clean-energy-technologies-inc-secures-144700111.html

    Clean Energy Technologies, Inc. Secures New Order for Waste Biomass Application in Europe
    COSTA MESA, Calif., July 12, 2017 /PRNewswire/ -- Clean Energy Technologies, Inc. (CETY) announced today that its subsidiary Heat Recovery Solutions has secured a new Clean CycleTM generator order for a Waste Biomass application in Europe. Growing d
    finance.yahoo.com
  • Anyone recognize the clockwork short action at open? Every other day it drops 4-5% right after open only to recover at close meaning the shorts are busy strobing their sells. If what I'm saying is true, watch the Wednesday drop from 5.54 to 5.34 before the eventual close near 5.60.
  • Option traders visit CreditSpreads.io, totally free live feed of mathematically profitable option credit spreads for the coming four weeks, sometimes including spreads for BCRX! High probability option credit spreads offer you a technique to invest with defined risk and the max profit received right away. CreditSpreads.io targets solely the credit spreads which meet its strict requirements for probability and profit, and contributes to continued profitability by telling you of any impending situations that may affect the trade. www.creditspreads.io

    CreditSpreads.io
    Sustainable, high probability, defined risk stock option trading opportunities.
    www.creditspreads.io
  • Nice upside today on the 4th of July weekend. will there be fireworks this week with the aebola virus outbreak????
  • (AXSM) Mcap $90 M /Cash $55 M / 5x Phase 3 programs in various indications targeting huge Markets with first results in Q3 2017 =10+ BAGGER ....GLTA ! Please readand realize the brutal potential !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)
    Price:$3.90

    Shares Out: 23.5 Million

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
  • from Motley Fool "Even after the drop, BioCryst still has gained more than 13% in the past two days, and many see more upside for the small biotech going forward." Good news. Big upside coming!
  • It's an ill plan that cannot be changed.http://dataunion.tistory.com/10597

    BioCryst Pharmaceuticals NASDAQ : BCRX Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.6 In other words, the correlation coefficient of the other stock
    dataunion.tistory.com
  • From Motley Fool article: "Unfortunately, BioCryst will need to raise capital well before initiating a late-stage trial for BCX7353, given its last stated cash position of $98 million and burn rate that already exceeds $43 million per year. In other words, there's a good chance that the company is going to take advantage of this spike in its share price to raise capital, perhaps within the next few days. So, until then, investors interested in this small-cap biotech stock may want to bide their time for a more attractive entry point. "
  • Classic short squeeze. A thing of beauty !
  • will be $9 in no time. $# squeeze baby!
  • So, when will the dilution occur? Friday after hours is a favorite time for a dilution. So, my guess is at least one more day of pumping the price up. Now, will the dilution be at 6.0 or maybe 5.5?
  • This is/was short squeeze. The data released today aren't even statistically significant - less than 20 patients. No one's going to say, awesome results, let me buy the company.
  • why this is soaring any good news or just PUMP and DUMP?
  • Nice pump on no real news. Just a slight change to previous Phase 2 release. Perfect pump for a follow-on dilution.
  • Bitcoins are very hot now, Buy CNXS now, MIKE TYSON owns it , and you can too